# colorectal cancer - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 7
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 3704
- Completion tokens: 20598
- Reasoning tokens: 
- Total tokens: 24302
- API requests reported: 
- Elapsed seconds: 207.036
- Final benchmark system: raw; file rank 5/5; original repeat 7; model vendor: DeepSeek

---
## Interpretation of prognostic transcriptomic results in colorectal cancer

The input is a **prognostic screen** in colorectal tumor tissue. A hazard ratio (HR) > 1 means higher expression of that gene is associated with **worse overall survival**; HR < 1 means higher expression is associated with **better overall survival**. Most genes have FDR < 0.05, but several have FDR between 0.05 and 0.076; those genes should be treated as suggestive rather than definitive.

---

## 1. Overall biological interpretation

The overall pattern points to a **dedifferentiation–mesenchymal–metabolic switch** associated with poor prognosis in colorectal cancer.

- **Poorer-survival genes** are enriched in mesenchymal/EMT-related genes (`ZEB1-AS1`, `TPM4`, `DCBLD2`, `ITGBL1`, `NT5E`, `INHBB`, `MAP1B`, `ABL2`, `MSLN`), growth-factor/PI3K–AKT signaling genes (`FGF19`, `AKT3`), and metabolic genes favoring glycolysis (`SLC2A3`/GLUT3).
- **Better-survival genes** are enriched in intestinal lineage/differentiation genes (`CDX2`, `CDX1`, `MYB`, `LGALS4`, `MYO5B`) and mitochondrial oxidative metabolism genes (`NDUFA9`, `ATP5B`, `ATP5G1`, `CS`, `OGDHL`, `COA3`, `TIMM13`, `PRELID2`).

Taken together, the data support a model in which aggressive colorectal tumors tend to **lose intestinal differentiation, acquire EMT/mesenchymal-invasive features, shift toward glycolytic metabolism, and possibly evade immune surveillance through CD73/adenosine signaling**. Tumors with better prognosis appear to retain **intestinal epithelial identity and oxidative mitochondrial metabolism**.

This is a prognostic association, not proof of causation.

---

## 2. Core biological programs

### Program 1: EMT / growth-factor-driven invasive mesenchymal program
**Direction:** Poor prognosis — risk-associated genes.

**Supporting genes:** `ZEB1-AS1`, `TPM4`, `DCBLD2`, `ITGBL1`, `NT5E`, `INHBB`, `MAP1B`, `ABL2`, `MSLN`, `FGF19`, `AKT3`.

**Pathway / ontology:** Hallmark Epithelial–Mesenchymal Transition; TGF-beta signaling (KEGG hsa04350); FGF signaling / PI3K-Akt signaling.

**Interpretation:**  
- `ZEB1-AS1` is an antisense lncRNA that can stabilize/upregulate ZEB1, a master EMT transcription factor.  
- `INHBB` encodes an activin/TGFβ-superfamily ligand and can promote SMAD-dependent EMT/invasion.  
- `ITGBL1`, `TPM4`, `ABL2`, and `MAP1B` support matrix interaction, actin/microtubule remodeling, and cell migration.  
- `NT5E`/CD73 is both a mesenchymal marker and an immunosuppressive enzyme.  
- `FGF19` and `AKT3` provide growth-factor and survival signaling that can cooperate with EMT.

**Evidence strength:** Moderate-to-strong because multiple independent genes converge on a well-defined oncogenic process.  
**Major limitation:** Many EMT/stromal genes can be expressed by cancer-associated fibroblasts or other stromal cells rather than tumor cells. The result could partly reflect tumor stromal content, not purely tumor-cell-intrinsic EMT.

---

### Program 2: Loss of intestinal epithelial differentiation
**Direction:** Better prognosis — protective genes.

**Supporting genes:** `CDX2`, `CDX1`, `MYB`, `LGALS4`, `MYO5B`, `PRR15L`, `CRYM`, `DNPEP`.

**Pathway / ontology:** GO: intestinal epithelial cell differentiation; intestinal lineage specification.

**Interpretation:**  
- `CDX2` and `CDX1` are master intestinal homeobox transcription factors.  
- `LGALS4` is a galectin expressed in differentiated enterocytes.  
- `MYO5B` is essential for enterocyte apical trafficking and brush-border integrity.  
- Higher expression of this set is associated with better survival, supporting the idea that **retention of intestinal differentiation is favorable**, while its loss marks aggressive/dedifferentiated tumors.

**Evidence strength:** Moderate-to-strong due to coherent lineage-specific biology.  
**Major limitation:** Some genes (`MYB`) have cell-context-dependent oncogenic functions; `CDX1` and `LGALS4` have FDR slightly above 0.05 and should be interpreted with caution.

---

### Program 3: Mitochondrial oxidative metabolism versus glycolytic switch
**Direction:** Mitochondrial oxidative metabolism genes are protective; `SLC2A3`/GLUT3 is risk-associated.

**Supporting genes:**  
- Protective: `NDUFA9`, `ATP5B`, `ATP5G1`, `ATP23`, `CS`, `MCCC2`, `OGDHL`, `COA3`, `TIMM13`, `PRELID2`, `PXMP2`, `ACSS2`, `DBI`, `GLYCTK`.  
- Risk: `SLC2A3`.

**Pathway / ontology:** KEGG Oxidative Phosphorylation (hsa00190); KEGG Citrate Cycle / TCA cycle; Hallmark Oxidative Phosphorylation.

**Interpretation:**  
- Multiple subunits/assembly factors for mitochondrial Complex I and ATP synthase are protective (`NDUFA9`, `ATP5B`, `ATP5G1`, `ATP23`).  
- TCA/mitochondrial metabolism genes (`CS`, `OGDHL`, `MCCC2`) are also protective.  
- In contrast, `SLC2A3`/GLUT3, a high-affinity glucose transporter supporting glycolysis, is associated with worse survival.  
- This fits a metabolic model in which **differentiated intestinal tumors retain oxidative mitochondrial metabolism**, whereas aggressive tumors shift toward glycolytic metabolism.

**Evidence strength:** Moderate-to-strong because many genes from multiple mitochondrial subsystems point in the same direction.  
**Major limitation:** Mitochondrial gene content can be influenced by tissue composition, tumor purity, and overall cellular metabolic state. Some genes, e.g. `ACSS2` and `DBI`, have context-dependent roles.

---

### Program 4: Tumor-immune microenvironment — antigen presentation versus CD73-mediated immunosuppression
**Direction:** Mixed: `NT5E` risk; `TAPBPL` and `LGALS9` protective.

**Supporting genes:** `NT5E`, `TAPBPL`, `LGALS9`, and exploratory `CCL15-CCL14|CCL15`.

**Pathway / ontology:** KEGG Antigen processing and presentation; adenosine signaling / CD73 pathway.

**Interpretation:**  
- `NT5E`/CD73 generates immunosuppressive adenosine; higher expression is associated with worse survival, consistent with immune evasion.  
- `TAPBPL` is involved in MHC class I antigen processing; higher expression is associated with better survival, suggesting that tumors with better antigen presentation may be more immunologically visible.  
- `LGALS9` is immune modulatory and context-dependent; its protective direction here is plausible but not robust enough to interpret mechanistically.

**Evidence strength:** Weak-to-moderate. This is the least robust program because only a few genes are clearly immune-related, and `LGALS9`/`CCL15` have context-dependent or conflicting literature roles.  
**Major limitation:** The input does not include immune-cell infiltration data, so these signals could reflect immune-cell content rather than tumor-cell properties.

---

## 3. Key genes and interaction modules

### 1. `CDX2` / `CDX1` module — protective
- `CDX2`: HR 0.748, FDR 0.036. `CDX1`: HR 0.781, FDR 0.057.
- Role: Master intestinal transcription factors; their loss is a marker of dedifferentiation.
- Relationship: Paralogous transcription factors that co-regulate intestinal differentiation genes. This is **pathway co-membership / shared regulatory role**, not necessarily direct physical interaction.

### 2. `ZEB1-AS1` / ZEB1 axis — risk
- HR 1.372, FDR 0.0087.
- Role: Antisense lncRNA that can positively regulate ZEB1, a key EMT transcription factor.
- Relationship: **Regulatory interaction** via antisense RNA mechanism, based on published evidence; direct interaction is not established from the current dataset.

### 3. `INHBB` — risk
- HR 1.433, FDR 0.0011.
- Role: Activin/TGFβ-superfamily ligand; can activate SMAD signaling and EMT.
- Relationship: Pathway co-membership with TGFβ/EMT program; no direct physical interaction with ZEB1 or CDX2 should be inferred.

### 4. `NT5E` / CD73 — risk
- HR 1.313, FDR 0.039.
- Role: Cell-surface enzyme converting AMP to adenosine; immunosuppressive and EMT-associated.
- Relationship: Indirect immune-microenvironment effect; not a direct protein interaction with TAPBPL.

### 5. `TAPBPL` — protective
- HR 0.711, FDR 0.019.
- Role: MHC class I antigen-processing/loading factor.
- Relationship: Opposite prognostic direction to `NT5E`; represents a different arm of the tumor–immune interaction, not a direct molecular interaction.

### 6. `FGF19` + `AKT3` growth signaling module — risk
- `FGF19`: HR 1.291, FDR 0.051. `AKT3`: HR 1.318, FDR 0.039.
- Role: FGF ligand and PI3K/AKT kinase; cooperate in survival, proliferation, and invasion.
- Relationship: Canonical **pathway co-membership** in FGF→PI3K/AKT signaling; direct physical interaction is not established.

### 7. Mitochondrial oxidative metabolism module — protective
- Representative genes: `NDUFA9` HR 0.689, FDR 0.0087; `CS` HR 0.754, FDR 0.039; `ATP5B` HR 0.748, FDR 0.059; `OGDHL` HR 0.686, FDR 0.074.
- Role: OXPHOS/TCA/mitochondrial maintenance.
- Relationship: **Pathway co-membership** in oxidative phosphorylation/TCA cycle. Some genes encode subunits of the same physical complexes, but the current data do not prove direct physical interactions.

### 8. `MIR31HG` — risk
- HR 1.309, FDR 0.0066.
- Role: lncRNA/host gene for miR-31; reported oncogenic roles in colorectal cancer.
- Relationship: Co-expression/risk-module relationship with other oncogenic lncRNAs; direct interactions are not established here.

### 9. `SLC2A3` / GLUT3 — risk
- HR 1.281, FDR 0.072.
- Role: High-affinity glucose transporter; supports glycolysis.
- Relationship: Opposes the mitochondrial oxidative metabolism module at the metabolic pathway level, not a direct gene–gene interaction.

### 10. `ABL2` — risk
- HR 1.301, FDR 0.028.
- Role: Non-receptor tyrosine kinase regulating actin dynamics, invasion, and EMT.
- Relationship: Pathway co-membership with EMT/cytoskeletal remodeling; likely indirect relationship with `ZEB1-AS1`.

---

## 4. Validation priorities

### Priority 1: Distinguish tumor-cell versus stromal/immune-cell origin of the risk signature  
**Classification:** Confounding / composition check  
**Why:** Many risk genes (`ITGBL1`, `NT5E`, `INHBB`, `MSLN`, `NPR3`) can be expressed by stromal or immune cells, whereas protective genes (`CDX2`, `CDX1`, `MYO5B`, `LGALS4`) are largely epithelial. The association could partly reflect tumor purity/stromal content.  
**Current evidence:** Coherent directional clustering but no cell-composition data.  
**External evidence:** CMS4/mesenchymal colorectal tumors have high stromal content and worse survival; CDX2 loss is a known poor-prognosis feature.  
**Next step:** RNA deconvolution, ESTIMATE/CIBERSORTx, multiplex IHC, or digital pathology for epithelial and stromal markers.  
**Confidence:** Supported hypothesis — composition almost certainly contributes, but the magnitude is unknown.

---

### Priority 2: Validate `CDX2`/`CDX1` intestinal differentiation as a prognostic biomarker  
**Classification:** Biomarker  
**Why:** This is one of the most biologically coherent protective modules and has direct clinical applicability.  
**Current evidence:** `CDX2` protective with FDR 0.036; `CDX1` protective with FDR 0.057; related genes `LGALS4` and `MYO5B` are also protective.  
**External evidence:** Loss of CDX2 by IHC is associated with poor prognosis in colorectal cancer.  
**Next step:** Independent cohort validation with CDX2 IHC, stratified by stage, MSI status, and consensus molecular subtype.  
**Confidence:** Supported hypothesis — especially for CDX2; the broader module requires additional validation.

---

### Priority 3: Test the `ZEB1-AS1`/ZEB1 regulatory axis in EMT  
**Classification:** Interaction / network hypothesis  
**Why:** `ZEB1-AS1` is strongly risk-associated and plausibly controls ZEB1, a central EMT transcription factor.  
**Current evidence:** `ZEB1-AS1` HR 1.372, FDR 0.0087.  
**External evidence:** ZEB1-AS1 has been reported to regulate ZEB1 expression in several cancer types; ZEB1-driven EMT promotes metastasis.  
**Next step:** RNA antisense interaction assays, ZEB1-AS1 knockdown in colorectal cancer cell lines/organoids, and measurement of EMT markers and invasive capacity.  
**Confidence:** Exploratory hypothesis for the specific CRC regulatory interaction; supported hypothesis for EMT association more broadly.

---

### Priority 4: Evaluate NT5E/CD73 as an immune-modulatory and therapeutic target  
**Classification:** Therapeutic target / mechanistic hypothesis  
**Why:** CD73 is the only clear immunosuppressive enzyme among the top risk genes and is clinically targetable, though drug availability alone is not evidence of efficacy.  
**Current evidence:** `NT5E` HR 1.313, FDR 0.039.  
**External evidence:** CD73-generated adenosine suppresses T-cell function; CD73 inhibitors are in clinical development; high CD73 has been associated with poor prognosis in some cancers.  
**Next step:** CD73 IHC and enzymatic activity assays, immune-infiltration analysis, and functional anti-CD73 or CD73-knockout studies in CRC models.  
**Confidence:** Supported hypothesis for prognostic association; therapeutic efficacy remains exploratory.

---

### Priority 5: Examine the mitochondrial oxidative metabolism versus glycolysis switch as a metabolic vulnerability  
**Classification:** Mechanistic hypothesis  
**Why:** The large set of protective mitochondrial genes and the risk-associated `SLC2A3`/GLUT3 suggest a metabolic shift relevant to aggressiveness.  
**Current evidence:** Many mitochondrial/OXPHOS genes are protective; `SLC2A3` is risk-associated but borderline.  
**External evidence:** Cancer metabolic reprogramming commonly favors glycolysis; some mitochondrial genes such as `OGDHL` have been reported as downregulated in cancers. However, OXPHOS can also support metastasis in some contexts, so evidence is context-dependent.  
**Next step:** Metabolic flux analysis, metabolomics, and functional perturbation of OXPHOS or GLUT3 in models with high versus low risk signatures.  
**Confidence:** Exploratory hypothesis.

---

## 5. Evidence grounding

The interpretation is supported by several evidence categories, but they are not fully independent:

- **Direct input evidence:** HR, P, FDR from the provided prognostic table.
- **Pathway/ontology evidence:** GO, KEGG, Reactome, and Hallmark annotations used to group genes.
- **Disease-association evidence:** Published colorectal cancer literature for CDX2, EMT, CD73, and metabolic reprogramming.
- **Expression/tissue evidence:** Known intestinal-epithelial expression of `CDX2`, `LGALS4`, `MYO5B` versus stromal/mesenchymal expression of genes such as `ITGBL1` and `NT5E`.
- **Regulatory evidence:** External evidence for ZEB1-AS1/ZEB1 antisense regulation; CDX2/CDX1 co-regulation of intestinal genes.
- **Drug/therapeutic evidence:** CD73 inhibitors in clinical development, but this does not by itself prove that CD73 is a useful target in this specific dataset.

Important caveat: the gene-level results and pathway annotations are not truly independent sources. Many pathway definitions and cancer-gene annotations derive from the same published literature. The most robust internal evidence is the **concordant direction of multiple genes across a coherent pathway**.

There are also conflicting gene-level signals. For example, `MYB` and `GMNN` are often associated with proliferation or oncogenic roles in other contexts, but they appear protective here. `PTPN14` is commonly linked to Hippo/YAP regulation and tumor suppression, yet it is risk-associated in this dataset. These conflicts should temper gene-by-gene interpretations.

---

## 6. Limitations and alternative explanations

### 1. Tissue/cell composition and tumor purity
Many risk genes could be expressed by cancer-associated fibroblasts, endothelial cells, or immune cells. Many protective genes are epithelial. The apparent survival associations may reflect the proportion of stroma or immune cells in the tumor sample rather than tumor-cell-intrinsic biology.

**How to investigate:** Deconvolution of bulk transcriptomes, IHC-based cell lineage markers, laser microdissection, or single-cell RNA-seq.

### 2. Association versus causation
This is an observational prognostic analysis. HRs do not demonstrate that a gene drives survival. Perturbation experiments are required before causal language is appropriate.

### 3. Unmeasured clinical confounders
Stage, MSI status, treatment exposure, age, sex, and tumor location are not provided in the input. If these are associated with gene expression, the HRs may be confounded.

**How to investigate:** Multivariable Cox models including clinicopathologic covariates in an independent cohort.

### 4. FDR and borderline significance
Several genes used in the interpretation, including `CDX1`, `LGALS4`, `FGF19`, `SLC2A3`, `OGDHL`, and `ATP5B`, have FDR between 0.05 and 0.076. These should be viewed as suggestive until independently validated.

### 5. Ambiguous probes and multi-gene features
The table contains several `PROBE_` entries and multi-gene features such as `LOC101928747|RBMX|SNORD61` and `MIR1248|SNORA81|SNORA4|SNORD2|SNORA63|EIF4A2`. These are difficult to assign to a single transcript and were not used as core evidence.

### 6. Broad and overlapping biological programs
The mitochondrial, differentiation, and EMT programs may overlap because they reflect general tissue phenotype rather than four fully independent pathways. For example, differentiated intestinal epithelial cells naturally express high levels of mitochondrial metabolism genes, so “differentiation” and “oxidative metabolism” may track the same underlying cell state.

---

## Overall conclusion

The dataset supports a coherent, biologically plausible model: **poor-prognosis colorectal tumors tend to lose intestinal differentiation, acquire EMT/mesenchymal-invasive properties, shift toward glycolytic metabolism, and may evade immunity via CD73; better-prognosis tumors tend to retain intestinal differentiation and mitochondrial oxidative metabolism.** However, the results are prognostic associations and should be interpreted as hypothesis-generating. The most pressing next steps are to resolve tumor-cell versus stromal contributions, validate the CDX2/CDX1 differentiation signal as a biomarker, and functionally test the EMT and CD73-related hypotheses.
